摘要： 对他汀类药物治疗组（他汀治疗组）或非他汀类药物治疗组（对照组）患者入院时和发病30 d 时临床资料进行分析，并比较两组血清超敏C-反应蛋白水平的变化。结果显示，他汀治疗组患者发病30 d 时血清超敏C-反应蛋白低于对照组（t = 9.925，P = 0.015），发病后3 个月预后优于对照组（χ² =4.762，P = 0.029）；经逐步Logistic 回归分析，入院时美国国立卫生研究院卒中量表评分（OR = 1.383，95%CI：1.062 ~ 1.800；P = 0.028）和发病48 h 血清超敏C-反应蛋白水平（OR = 1.472，95%CI：0.500 ~ 4.370；P =0.001）对患者发病3 个月时的预后具有独立预测作用。提示他汀类药物可以降低急性缺血性卒中患者血清超敏C-反应蛋白水平，对发病3 个月时的预后具有预测作用。

关键词: 卒中, C 反应蛋白质, 降血脂药, 预后

Abstract: The clinical data of 100 patients with acute ischemic stroke on admission and 30 d after stroke were analyzed. The patients were evenly divided into 2 groups (statin group and control group). Serum high-sensitivity C-reactive protein (hs-CRP) level was similar in the 2 groups within 48 h after onset, but was significantly lower in statin group 30 d after onset (t = 9.925, P = 0.015). The statin group also had better 3-month outcome ( χ² = 4.762, P = 0.029). After using stepwise Logistic regression analysis, only National Institute of Health Stroke Scale (NIHSS) score on admission (OR = 1.383, 95%CI: 1.062-1.800; P = 0.028) and hs-CRP in the acute phase (OR = 1.472, 95%CI: 0.500-4.370; P = 0.001) were significantly and independently predictive for 3-month outcome. This study indicates that statin therapy reduces hs-CRP level in the acute phase and can predict the 3-month clinical outcome of ischemic stroke.

Key words: Stroke, C-reactive protein, Antilipemic agents, Prognosis